Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
3.120
-0.180 (-5.45%)
At close: Oct 30, 2026, 4:00 PM EDT
3.130
+0.010 (0.32%)
After-hours: Oct 30, 2026, 7:50 PM EDT
Anixa Biosciences Employees
Anixa Biosciences had 4 employees as of October 31, 2025. The number of employees decreased by 1 or 20.00% compared to the previous year. That makes Anixa Biosciences the 42,100th largest employer in the world and 6,645th in the United States.
Employees
4
Change (1Y)
-1
Growth (1Y)
-20.00%
Revenue / Employee
n/a
Profits / Employee
-$2,595,500
Market Cap
108.46M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Oct 31, 2025 | 4 | -1 | -20.00% | 4 | 0 |
| Oct 31, 2024 | 5 | 0 | - | 5 | 0 |
| Oct 31, 2023 | 5 | 0 | - | 4 | 1 |
| Oct 31, 2022 | 5 | 0 | - | 4 | 1 |
| Oct 31, 2021 | 5 | 1 | 25.00% | 4 | 1 |
| Oct 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Oct 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 184 |
| Voyager Therapeutics | 141 |
| Nkarta | 106 |
| PolyPid | 75 |
| OnKure Therapeutics | 45 |
| Anavex Life Sciences | 34 |
| Unicycive Therapeutics | 22 |
| PDS Biotechnology | 21 |
ANIX News
- 6 days ago - Anixa Biosciences completes treatment of fifth cohort in ovarian cancer trial - TheFly
- 6 days ago - Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial - PRNewsWire
- 19 days ago - Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference - PRNewsWire
- 27 days ago - Anixa Biosciences reports first case of stable disease in CAR-T trial - TheFly
- 27 days ago - Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial - PRNewsWire
- 4 weeks ago - Anixa Biosciences says second patient treated in CAR-T ovarian cancer trial - TheFly
- 4 weeks ago - Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial - PRNewsWire
- 5 weeks ago - Anixa Biosciences price target lowered to $6 from $7 at H.C. Wainwright - TheFly